NCT06928389

Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer

A Randomized, Double-blind, Multicenter Phase 3 Clinical Trial of Ivonescimab Versus Placebo, Combined With Docetaxel in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) That Has Progressed on or After PD-(L)1 Inhibitor-based Therapy

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 536 (estimated)
• Sponsor: Akeso · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a Phase 3 Randomized, double-blind, Multicenter Study of Ivonescimab Combined with Docetaxel Versus Placebo Combined with Docetaxel in Patients with Locally advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) that has progressed on or after PD-(L)1 inhibitor-based therapy. The purpose of this study is to evaluate the efficacy and safety of ivonescimab versus placebo, combined with docetaxel in patients with advanced NSCLC.

Conditions

• Non-Small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	Ivonescimab, docetaxel	Patients will receive ivonescimab and docetaxel as an IV injection
DRUG	Placebo, docetaxel	Patients will receive placebo and docetaxel as an IV injection

Timeline

• Start date: 2025-07-08
• Primary completion: 2027-05-01
• Completion: 2030-06-01
• First posted: 2025-04-15
• Last updated: 2026-04-09

Locations

1 site across 1 country: China